MarketCap
DiaMedica Therapeutics DMAC
$ 7.94
1.4%
Facebook
X
Telegram
DiaMedica Therapeutics Current Ratio | DMAC
Annual Current Ratio DiaMedica Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 13.8 | 6.7 | 13.9 | 1.49 | 2.96 | 0.196 | 0.147 | 1.72 | 1.56 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.9 | 0.147 | 4.71 |
Current Ratio of other stocks in the Biotechnology industry
| Issuer | Current Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AnaptysBio
ANAB
|
12.8 | $ 51.0 | 1.83 % | $ 1.48 B |  USA |
 |
Allakos
ALLK
|
5.43 | - | - | $ 28.6 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
4.64 | $ 1.88 | 0.53 % | $ 107 M | USA |
 |
Clovis Oncology
CLVS
|
0.629 | - | -7.23 % | $ 13 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
3.11 | - | - | $ 401 M | USA |
 |
Evelo Biosciences
EVLO
|
0.928 | - | -14.46 % | $ 27.9 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
5.04 | $ 60.26 | 0.06 % | $ 11.6 B | USA |
 |
BioNTech SE
BNTX
|
7.95 | $ 98.52 | 0.24 % | $ 23.8 B |  Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.76 | $ 2.17 | 0.46 % | $ 3.57 M |  Israel |
 |
Freeline Therapeutics Holdings plc
FRLN
|
2.53 | - | - | $ 384 M |  Britain |
 |
Genocea Biosciences
GNCA
|
1.94 | - | -15.0 % | $ 3.04 M | USA |
 |
Catalyst Biosciences
CBIO
|
6.97 | $ 13.99 | 0.84 % | $ 1.25 B | USA |
 |
C4 Therapeutics
CCCC
|
3.5 | $ 2.98 | 0.3 % | $ 247 M | USA |
 |
Codexis
CDXS
|
1.52 | $ 1.32 | 1.09 % | $ 115 M | USA |
 |
Amryt Pharma plc
AMYT
|
1.78 | - | - | $ 621 M | Britain |
 |
Cerus Corporation
CERS
|
1.41 | $ 2.62 | 0.38 % | $ 499 M | USA |
 |
G1 Therapeutics
GTHX
|
1.41 | - | - | $ 370 M | USA |
 |
Coherus BioSciences
CHRS
|
1.31 | $ 1.13 | 0.43 % | $ 132 M | USA |
 |
Celldex Therapeutics
CLDX
|
10.4 | $ 31.1 | 1.16 % | $ 2.07 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
2.29 | $ 4.25 | 3.16 % | $ 51.9 M | Israel |
 |
Cellectar Biosciences
CLRB
|
2.96 | $ 1.8 | 0.72 % | $ 4.69 M | USA |
 |
AbbVie
ABBV
|
3.18 | $ 264.34 | 0.09 % | $ 468 B | USA |
 |
Humanigen
HGEN
|
0.193 | - | -81.12 % | $ 4.28 M | USA |
 |
Cocrystal Pharma
COCP
|
2.87 | $ 1.17 | 1.74 % | $ 13.2 M | USA |
 |
AbCellera Biologics
ABCL
|
3.48 | $ 12.7 | 0.4 % | $ 3.79 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
3.64 | $ 5.4 | 2.65 % | $ 286 M | USA |
 |
Collegium Pharmaceutical
COLL
|
1.22 | $ 22.53 | 0.2 % | $ 713 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
4.43 | $ 116.1 | 4.93 % | $ 12.1 B | USA |
 |
Фармсинтез
LIFE
|
0.454 | - | - | - |  Russia |
 |
IGM Biosciences
IGMS
|
1.22 | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
0.826 | - | - | $ 13.1 M | Canada |
 |
Kinnate Biopharma
KNTE
|
12.2 | - | - | $ 123 M | USA |
 |
Cardiff Oncology
CRDF
|
3.75 | $ 1.24 | 0.74 % | $ 82.9 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
8.41 | - | - | $ 231 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
8.13 | $ 7.14 | 0.19 % | $ 95.1 M | USA |
 |
Karuna Therapeutics
KRTX
|
16.3 | - | - | $ 12.2 B | USA |
 |
Curis
CRIS
|
1.38 | $ 0.83 | 1.1 % | $ 10.9 M | USA |
 |
CorMedix
CRMD
|
1.96 | $ 7.85 | 1.03 % | $ 565 K | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
8.39 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
6.6 | $ 54.23 | 0.23 % | $ 4.88 B |  Schweiz |
|
Champions Oncology
CSBR
|
1.18 | $ 4.9 | 0.1 % | $ 67.8 M | USA |
 |
Chimerix
CMRX
|
6 | - | - | $ 756 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
7.17 | $ 11.62 | 8.21 % | $ 918 M | USA |
 |
Cue Biopharma
CUE
|
2.68 | $ 31.41 | 1.45 % | $ 2.98 B | USA |
 |
CEL-SCI Corporation
CVM
|
2.31 | $ 1.67 | 2.38 % | $ 13.4 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
5.24 | $ 4.85 | 0.2 % | $ 929 M | Canada |
 |
Cytokinetics, Incorporated
CYTK
|
0.684 | $ 64.66 | 0.17 % | $ 7.77 M | USA |
 |
Daré Bioscience
DARE
|
1.1 | $ 0.78 | 4.73 % | $ 8.72 M | USA |
 |
Adagene
ADAG
|
2.97 | $ 2.93 | 2.86 % | $ 173 M |  China |